| Title |
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, October 2011
|
| DOI | 10.1007/s00280-011-1759-9 |
| Pubmed ID | |
| Authors |
Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Samuel R. Denmeade, Susan F. Slovin, Kathy Jelaca-Maxwell, Martha E. Vincent, Howard I. Scher, Michael J. Morris |
| Abstract |
AGS-1C4D4 is a human monoclonal antibody against prostate stem cell antigen (PSCA), a cell-surface protein expressed by most prostate cancers. AGS-1C4D4 is produced in Chinese hamster ovary (CHO) cells and has an identical sequence to AGS-PSCA, an anti-PSCA antibody produced in mouse hybridoma cells that has completed Phase I testing. Preclinical studies demonstrated comparability of AGS-1C4D4 to AGS-PSCA with respect to pharmacokinetics (PK) and tumor inhibition. However, because of differences in antibody-dependent cellular cytotoxicity between AGS-PSCA and AGS-1C4D4, a limited Phase I trial using AGS-1C4D4 was performed evaluating safety and PK. |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 48 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 22% |
| Researcher | 7 | 14% |
| Student > Bachelor | 6 | 12% |
| Student > Doctoral Student | 5 | 10% |
| Other | 4 | 8% |
| Other | 11 | 22% |
| Unknown | 5 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 35% |
| Agricultural and Biological Sciences | 7 | 14% |
| Immunology and Microbiology | 4 | 8% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Computer Science | 2 | 4% |
| Other | 9 | 18% |
| Unknown | 8 | 16% |